King's Research Portal

DOI:

[10.1007/s40629-016-0116-2](https://doi.org/10.1007/s40629-016-0116-2)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Eberlein, B., Santos, A. F., Mayorga, C., Nopp, A., Ferrer, M., Rouzaire, P., Ebo, D., Sabato, V., Sanz, M. L., Pecaric-Petkovic, T., Patil, S. U., Hausmann, O. V., Shreffler, W. G., Korosec, P., Knol, E. F., & Hoffmann, H. J. (2016). Basophil activation testing in diagnosis and monitoring of allergic disease - An overview. *Allergo Journal*, 25(4), 26-33. <https://doi.org/10.1007/s40629-016-0116-2>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

1 Basophil Activation Testing in Diagnosis and Monitoring of Allergic Disease – an overview

2 Eberlein B^{1*}, Santos AF^{2,3,4}, Mayorga C⁵, Nopp A⁶, Ferrer M⁷, Rouzair P⁸, Ebo D⁹, Sabato V⁹,
 3 Sanz ML⁷, Pecaric-Petkovic T¹⁰, Patil SU¹¹, Hausmann OV^{12,13}, Shreffler WG¹¹, Korosec P¹⁴, Knol
 4 EF¹⁵, Hoffmann HJ¹⁶

5 Affiliations:

6 1. Department of Dermatology and Allergy Biederstein, Technische Universität München, Munich,
 7 Germany

8 2. Department of Paediatric Allergy, Division of Asthma, Allergy and Lung Biology, King's
 9 College London, London, UK

10 3. MRC & Asthma UK Centre in Allergic Mechanisms of Asthma, London, United Kingdom

11 4 Immunoallergology Department, Coimbra University Hospital, Coimbra, Portugal

12 5. Research Laboratory and Allergy Service, IBIMA-Regional University Hospital of Malaga,
 13 UMA, Malaga, Spain

14 6. Clinical Immunology and Allergy Unit, Department of Medicine Solna, Karolinska Institutet,
 15 Karolinska University Hospital, Stockholm, Sweden

16 7. Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, Pamplona,
 17 Spain

18 8. Department of Immunology, University Hospital, Clermont-Ferrand and ERTICa Research
 19 Group, University of Auvergne EA4677, Clermont-Ferrand, France

20 9. Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp
 21 University Hospital, Antwerp, Belgium

22 10. Adverse Drug Reactions-Analysis and Consulting (ADR-AC) GmbH, Bern, Switzerland

23 11. Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and
 24 Harvard Medical School, Boston, Massachusetts, United States

25 12. Department of Rheumatology, Immunology and Allergology, Inselspital, University of Bern,
26 Bern, Switzerland

27 13. Loewenpraxis, Luzern, Switzerland

28 14. Laboratory for Clinical Immunology & Molecular Genetics, University Clinic of Respiratory
29 and Allergic Diseases Golnik, Golnik, Slovenia

30 15. Department of Immunology and Department of Dermatology/Allergology. University Medical
31 Center Utrecht, Utrecht, The Netherlands

32 16. Department of Respiratory Diseases and Allergy, Department of Clinical Medicine, Aarhus
33 University, Aarhus, Denmark

34

35

36 * Address correspondence to Bernadette Eberlein, M.D., Professor, Department of Dermatology
37 and Allergy Biederstein, Technische Universität München, Biedersteiner Str. 29, D 80802
38 München, telephone + 49-8941403324, e-mail bernadette.eberlein@tum.de

39

40 Keywords

41 1. Basophil granulocyte

42 2. CD63

43 3. BAT, Basophil activation test

44 4. Allergy Diagnosis

45 5. Allergy monitoring

46 6. Allergen provocation /challenge testing

47

48

49

50

51

52

53

54

55

56

57

Abstract

The nature of basophil activation as an ex vivo challenge makes it a multifaceted and promising tool for the allergist. Through development of flow cytometry, discovery of activation markers such as CD63 and markers identifying basophil granulocytes the basophil activation test (BAT) has become a pervasive test. BAT measures basophil response to allergen crosslinking IgE on between 150 and 2000 basophil granulocytes with remarkable analytical sensitivity in less than 0.1 ml fresh blood. Dichotomous activation is assessed as the fraction of reacting basophils. In patients with food-, insect venom-, and drug allergy as well as with chronic urticaria BAT can be part of the diagnostic evaluation in addition to history, skin prick testing and specific IgE determination. BAT may be also helpful in determining the clinically relevant allergen. Basophil sensitivity may be used to monitor patients on allergen immunotherapy, anti-IgE treatment or in the natural resolution of allergy. The test may use fewer resources and be more reproducible than oral, sting, nasal or bronchial challenge testing. BAT may be useful before challenge testing as it is less stressful for the patient and avoids severe allergic reactions. An important prospective step is to standardize BAT and make it available in diagnostic laboratories.

95 **Introduction**

96
97 The clinical impact of BAT is due to the unique ability of basophils to degranulate upon cross-
98 linking of the specific IgE (sIgE) bound on membrane-bound high affinity IgE-receptor (FcεRI) by
99 allergen exposure. After discovery of the quantal upregulation of CD63 during basophil activation
100 in 1991(1), the BAT was developed in the 90's (2). CD63 is a membrane protein localized to the
101 same secretory lysosomal granule that contains histamine. Translocation of CD63 to the cell
102 membrane during degranulation can be measured by flow cytometry. BAT (like SPT) reflects a
103 functional response as basophil (or skin mast cell) activation can be induced by cross-linking of
104 FcεRI.

105 In this overview, adapted from the EAACI Task force position paper (3) we provide an overview of
106 the practical and technical details as well as the utility of BAT in diagnosis and management of
107 allergic diseases.

108

109 *Blood samples for BAT*

110
111 Antihistamines do not interfere with BAT, but systemic steroids and cyclosporin A should be
112 avoided (4,5). It is recommended to take blood samples within one year of the most recent exposure
113 to the allergen source (6,7). Blood samples can be used within 24 hours (8), even though basophils
114 may lose reactivity. As there is diurnal variation in the reactivity to CD203c (9), timing of blood
115 sampling may be important. Tests done with whole blood are most commonly utilized, but
116 separation of cells from protective elements found in plasma may optimize activation through cell-
117 bound sIgE.

118 Interleukin-3 (IL-3) enhanced kinetics, reactance and sensitivity of blood basophils to FcεRI
119 mediated activation independently of extracellular Calcium. It enhances also the allergen specific
120 up-regulation of CD63 (4,10), but unspecifically upregulates CD203c (11).

121

122 *Selection of the source of allergen extracts (Box 1)*

123 Optimized concentrations for a wide range of allergens, allergen sources and allergen extracts
 124 are listed in the original position paper in table S1 (3). Furthermore, optimized allergen
 125 preparations are available from vendors. Drug allergens are typically active in the mg/ml range,
 126 and can be diluted 5- to 25-fold. Pure active ingredients or injectable intravenous drug preparations
 127 should be used when possible since solubilized tablets are complex mixtures of drugs and
 128 excipients.

129 Protein allergens are often used in concentrations starting in the µg/mL range, and may be diluted
 130 up to 5 – 15 log concentrations to ng/ml - pg/ml before reactivity is lost. If recombinant allergen
 131 preparation or purified allergens are used for BAT, the molar concentration of allergens enables
 132 very precise analyses.

133 This standardized allergen preparation is essential when comparing basophil sensitivity data.

134 *Flow Cytometry in BAT*

135
 136 At the moment BAT with CD63 is the best clinically validated test (12,13,14), but the BAT
 137 based on CD203c has been shown to be a reliable test (15,16).

138 Basophils can be identified with different combinations of antibodies in flow cytometry. They
 139 were first identified as circulating IgE⁺ cells. However, low side scatter in combination with
 140 CD123⁺/HLADR⁻, CRTH2⁺, CD203c⁺ or CD193⁺ are commonly applied combinations. Cell
 141 surface expression of the basophil selection marker CD193 (CCR3) was more stable than IgE
 142 or CD123/HLA DR on resting basophils (17). IgE and CD123/HLA-DR showed somewhat
 143 more inter-individual variability in cell surface expression. CD203c can be used for both
 144 identification and as an activation marker. Quality of blood basophils obtained is usually
 145 confirmed by stimulation with the bacterial peptide fMLP. Anti-IgE or anti-FcεRI antibodies
 146 are used as IgE-mediated positive controls, buffer as negative control.

147 If standardized commercial tests are not used, the method used for testing has to undergo
 148 validation.

149

150 *Presentation and interpretation of BAT*

151 There are two common measures of basophil activity; basophil reactivity (2), the number of

basophils that respond to a given stimulus, and basophil sensitivity (1, 18), the allergen concentration at which half of all reactive basophils respond (Fig. 1A). Basophil reactivity depends on the priming state of the basophil and the cellular translation of the IgE signal within the cell (19). It is sufficient to measure reactivity at one or two concentrations, and assessment of basophil reactivity is important using a positive control before basophil sensitivity to allergen is measured.

Basophil sensitivity is a function of reactivity and the compound affinity of cell-bound sIgE for allergen and free competing immunoglobulin. It requires measurement of reactivity at 6-8 allergen concentrations. The graded response to allergen is fitted to a curve of reactivity versus allergen concentration, and the eliciting concentration at which 50% of basophils respond (EC50) is determined (Fig. 1 B). EC50 can be expressed as 'CD-sens' by inversion and multiplication by 100 (20).

More recently the area-under-the-dose curve (AUC) measurement attempts to combine reactivity and sensitivity into one (Fig. 1C); it is similar to a coordinate system of sensitivity and reactivity, but also incorporates partial anergy induced at high allergen concentrations and can be calculated even in cases where responses do not fit well to a typical dose-response curve (21). ROC curves are used in identification of novel allergens when ≥ 7 sensitized patients are available.

Basophil granulocytes of non-responders (6%-17% of population) can remain unresponsive to stimulation through Fc ϵ RI. It is attributed to differences in the intracellular signaling pathway. Results from non-responder patients should be regarded as false negatives.

Placing BAT in the diagnostic algorithm for allergic disease

In the general algorithm for diagnosis of allergy (Box 2), patient history should be taken with an attempt to identify the allergen source and assess the severity of the allergic reaction. The allergic response should be confirmed by measurement of sIgE, skin prick testing and, for insect venom and drug allergy, intradermal testing. Measurement of sIgE may not be possible if the allergen source is not available as a routine reagent, and may be of limited value depending on the performance of the available reagents. BAT is a functional test resembling

181 an *ex vivo* IgE-mediated cellular response . It can be measured at the same time as sIgE, and in
 182 general precedes *in vivo* provocation tests.

183

184 **Chronic Urticaria**

185 The mechanism of chronic spontaneous urticaria (CU) is still incompletely understood. About half
 186 of the patients have autoantibodies against FcεRI and a few against IgE. CU sera activate resting
 187 basophils of normal donors to upregulate CD63 and CD203c. BAT may replace the autologous
 188 serum skin test (ASST) (22).

189 BAT with CD63 upregulation as an activation marker for CU was established as a specific,
 190 sensitive and safe *in vitro* alternative to detect functional autoantibodies (10, 23, 24). The central
 191 problem is the heterogeneity of the results using different basophil donors. This can be normalized
 192 by titrated addition of IL-3 (10). BAT with autologous basophils should not be performed because
 193 CU patients are often non responders or poor responders to IgE crosslinking and have diagnostic
 194 basopenia.

195 *Key messages*

- 196 • BAT may replace ASST as the standard diagnostic procedure to identify autoreactive serum
- 197 factors in CU with a quantifiable result that may be used to monitor treatment.
- 198 • BAT removes the risk of accidental infection.
- 199 • In contrast to ASST, there is no need to suspend antihistamines, as they do not influence the
- 200 result of BAT.

201

202 **Drug Allergy**

203 The diagnostic work-up of drug hypersensitivity reactions (DHR) aims to identify the culprit agent,
 204 identify cross-reactive drugs and to determine a safe alternative drug (25). Here BAT is an
 205 additional tool that is safer, gentler and cheaper than a challenge and, in some instances, is the only
 206 available diagnostic tool. The sensitivity of BAT in diagnosis of drug allergy is about 50%, and the
 207 specificity up to 93%.

208 There are several studies including BAT in drug allergy diagnosis for beta-lactams, NMBA,
 209 quinolones, radio contrast media and pyrazolones with good sensitivity and specificity.

BAT provides positive results in 40% of the patients with immediate-type systemic reaction and negative skin test and confirmed by provocation that constitute about 25% of all beta-lactam-allergic patients. BAT has also a good negative predictive value, useful in the decision to perform the provocation test as demonstrated with quinolones. Furthermore, it has a complementary role to skin tests for different drug hypersensitivities and can be particularly useful in the study of cross-reactivity between NMBA, for the identification of safe alternatives for future surgery (25, 26).

Key Messages

- For a number of drugs, BAT is the only available test to confirm a hypersensitivity response.
- A negative test does not rule out that the patient reacts to a metabolite of the drug.
- It may be difficult to confirm the clinical history of hypersensitivity by BAT after 18 months from the most recent clinical reaction.
- Once the hypersensitivity is established, cross-reacting drugs and safe alternatives may be suggested by BAT.

Food allergy

The performance of BAT in the diagnosis of food allergies has been assessed in various studies. The reported sensitivity of BAT ranges from 77-98%, and the specificity from 75-100%. BAT in these studies was more accurate than sSPT and sIgE (27, 28). For single individuals BAT sensitivity seems to allow a risk estimation for severe clinical reactions: In peanut allergy, BAT significantly improved clinical diagnosis over the use of SPT and sIgE and reduced the number of OFC required. BAT showed 100% specificity, suggesting that in patients with a positive BAT the OFC could be deferred (29).

Patients with clinical allergy that developed symptoms in an OFC to peanut had high basophil sensitivity to peanut, and patients who tolerated peanuts in a OFC had low basophil sensitivity to peanut. Although OFC and basophil sensitivity both identified all clinically sensitized children, only basophil sensitivity was reproducible at two consecutive visits ($r^2=0.94$). In a recent publication, BAT reactivity reflected the allergy severity and BAT sensitivity reflected the threshold of response to the allergen source in an OFC (30).

240

241 It has been shown that basophil reactivity distinguish patients that tolerate extensively heated forms
242 of cow's milk and egg from patients who do not. BAT may be useful in assessing the natural
243 resolution of food allergies that are commonly outgrown over time, such as cow's milk allergy (28),
244 and in determining when the food can safely be reintroduced in the diet. BAT has also been used to
245 monitor clinical response to immune-modulatory treatment of food allergy.

246 Basophil CD203c expression has shown to decrease during treatment with Omalizumab and to
247 return to pre-treatment levels after cessation of therapy in patients with peanut allergy (31). Also
248 improvement in basophil sensitivity to milk of milk allergic children treated with Omalizumab
249 predicted tolerance in a milk challenge test.

250

251

252 *Key messages*

- 253 • BAT can improve the diagnosis of food allergy in addition to SPT and sIgE and may be
254 able to reduce the number of OFC.
- 255 • BAT can be used to monitor the natural resolution and clinical response to immune-
256 modulatory treatments for food allergy.

257

258 **Hymenoptera venom allergy**

259 Overall, the diagnostic sensitivity of BAT with insect venoms referred to the history was found to
 260 be 85%-100%, the diagnostic specificity 83%-100% (13,14,15). Specific diagnostic problems can
 261 be resolved by measuring basophil reactivity and sensitivity.

262 *BAT in patients with negative standard tests:* A subset of patients (4-6%) with a history of systemic
 263 reactions after Hymenoptera stings have negative venom-specific IgE and skin test results. BAT
 264 allows the identification of about two thirds of those patients (32).

265 *BAT in patients sensitized to bee and wasp venom “double positivity”:* Up to 60% of the patients
 266 with Hymenoptera venom allergy have sIgE to both bee and wasp venom. Basophil reactivity has
 267 the lowest rate of double positivity of diagnostic tests for hymenoptera allergy (33) and repeatedly
 268 shows a positive result to only one venom in about one-quarter to one-third of patients with double
 269 sIgE positivity (13 34). In the case of patients with double positive BAT, the venom to which the
 270 patient is markedly more sensitive might represent the primary sensitizing allergen source, but this
 271 requires further research. BAT adds more clinically relevant information about the culprit insect
 272 than component-resolved sIgE testing with single recombinant allergens (32, 34). However,
 273 recombinant venom allergens applied to BAT might represent a step forward in developing better in
 274 vitro tests for specific diagnosis of Hymenoptera allergy.

275 *Monitoring the effect of venom immunotherapy with basophil sensitivity:* A clear decrease in
 276 basophil sensitivity is found up to 4 years after initiation of VIT, without a change in basophil
 277 reactivity. A recent report about an 8-year follow up of patients submitted to VIT showed that the
 278 decrease in basophil sensitivity seemed to be also associated with the induction of tolerance (35).
 279 Some studies suggest that side effects during the build-up phase of VIT are predicted by a high
 280 basophil sensitivity (36).

281 *Key messages*

- 282 • Basophil reactivity and sensitivity (in that order) play an important role in the diagnosis of
- 283 venom allergy, as they are effective tools to identify the primary sensitizing antigen.
- 284 • The utility of basophil sensitivity as the tool of choice to monitor the effect of VIT should be
- 285 explored.

286

287 **Inhalant allergens**

288 Determination of sIgE or skin testing in combination with the clinical history are usually sufficient
 289 to diagnose allergy to inhalant allergens. However, in specific cases BAT can be helpful for
 290 diagnosis. Patients with local allergic rhinitis by nasal provocation who have no detectable sIgE or
 291 skin testing but have a positive BAT are a notable example (37). Crude allergen sources as well as
 292 modified and recombinant allergens have been tested with good outcomes, Basophil sensitivity
 293 correlates with the nasal provocation titer in allergic rhinitis (38), the allergen specific bronchial
 294 provocation threshold in allergic asthma and the asthma control test. This indicates that basophil
 295 allergen threshold sensitivity (CD-sens or EC50) may accurately reflect clinical allergen sensitivity
 296 (39).

297 *Monitoring the effect of allergen immunotherapy and anti-IgE treatment effect:* Basophil
 298 sensitivity can be used to assess the efficacy of allergen-specific immunotherapy (AIT) to
 299 aeroallergens. It has been used to monitor patients treated with AIT for birch and timothy (18,19),
 300 and showed reduced allergen sensitivity already during the up-dosing stage. Basophil sensitivity has
 301 also successfully been used to identify patients who respond to the humanized monoclonal anti-IgE
 302 antibody Omalizumab and to assess treatment efficacy (40).

303 *Key message*

- 304 • Basophil sensitivity has the unique ability to monitor a patient's inhalant allergen sensitivity
- 305 over time, to measure natural progression of allergy, and may be developed to serve as a
- 306 tool to measure the response to treatment with AIT and Omalizumab.

307 308 *Perspectives*

309 Different methods of reporting results of BAT may be useful when asking different clinical
 310 questions; stimulation index and % positive basophils are used. When reactivity is measured in
 311 clinical settings, the aim is usually to identify an allergen concentration at which change in
 312 sensitivity is optimally identified. Basophil sensitivity is used to monitor change in allergic disease.
 313 Both reactivity and allergen sensitivity are measured when allergy severity is evaluated by basophil
 314 sensitivity, but a useful composite measure has yet to be designed.

315 A threshold for basophil reactivity is often set at 2%, 10% or 15% of resting basophils. An
316 alternative method would be to set the threshold halfway between the MFI of resting basophils and
317 the positive control.

318 Major applications of BAT are summarized in Box 4. Laboratory procedures and allergen
319 concentrations in BAT should be standardized e.g by the use of industry standards like MiFlowCyt
320 or purchase of standardized material from CE-approved vendors. An important next step is the
321 standardization and automation of analysis of BAT. Then it will be possible to perform large
322 multicenter trials to characterize the diagnostic performance of BAT and broaden its use as a
323 clinical tool. Such studies should also address the relationship of measures of BAT and sensitivity
324 to sIgE, clinical symptoms and symptom severity.

325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354

References

1. Knol EF, Mul FP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. *J Allergy Clin Immunol* 1991;88:328–338
2. Sainte-Laudy J, Vallon C, Guérin JC. [Analysis of membrane expression of the CD63 human basophil activation marker. Applications to allergologic diagnosis]. *Allerg Immunol (Leipz)* 1994;26:211–214
3. Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. *Allergy* 2015; doi: 10.1111/all.12698. [Epub ahead of print]
4. Sturm EM, Kranzelbinder B, Heinemann A, Groselj-Strele A, Aberer W, Sturm GJ. CD203c-based basophil activation test in allergy diagnosis: characteristics and differences to CD63 upregulation. *Cytometry B Clin Cytom* 2010;78:308–318
5. Iqbal K, Bhargava K, Skov PS, Falkenchrone S, Grattan CE. A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria. *Clin Transl Allergy* 2012;2:19
6. Kvedariene V, Kamey S, Ryckwaert Y, Rongier M, Bousquet J, Demoly P et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. *Allergy* 2006;61:311–315
7. Fernández TD, Torres MJ, Blanca-López N, Rodríguez-Bada JL, Gomez E, Canto G et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. *Allergy* 2009;64:242–248
8. Sousa N, Martínez-Aranguren R, Fernández-Benitez M, Ribeiro F, Sanz ML. Comparison of basophil activation test results in blood preserved in acid citrate dextrose and EDTA. *J Investig Allergol Clin Immunol* 2010;20:535–536
9. Ando N, Nakamura Y, Ishimaru K, Ogawa H, Okumura K, Shimada S et al. Allergen-specific basophil reactivity exhibits daily variations in seasonal allergic rhinitis. *Allergy* 2015;70:319–322
10. Gentinetta T, Pecaric-Petkovic T, Wan D, Falcone FH, Dahinden CA, Pichler WJ et al. Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria. *J Allergy Clin Immunol* 2011;128:1227–1234.
11. Bühring H-J, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. *Int Arch Allergy Immunol* 2004;133:317–329
12. De Weck AL, Sanz ML, Gamboa PM, Aberer W, Bienvenu J, Blanca M et al. Diagnostic tests based on human basophils: more potentials and perspectives than pitfalls. *Int Arch Allergy Immunol* 2008;146:177–189

13. Sturm GJ, Böhm E, Trummer M, Weiglhofer I, Heinemann A, Aberer W. The CD63 basophil activation test in Hymenoptera venom allergy: a prospective study. *Allergy* 2004;59:1110–1117
14. Erdmann SM, Sachs B, Kwiecien R, Moll-Slodowy S, Sauer I, Merk HF. The basophil activation test in wasp venom allergy: sensitivity, specificity and monitoring specific immunotherapy. *Allergy* 2004;59:1102–1109
15. Eberlein-König B, Varga R, Mempel M, Darsow U, Behrendt H, Ring J. Comparison of basophil activation tests using CD63 or CD203c expression in patients with insect venom allergy. *Allergy* 2006;61:1084–1085
16. Ocmant A, Peignois Y, Mulier S, Hanssens L, Michils A, Schandené L. Flow cytometry for basophil activation markers: the measurement of CD203c up-regulation is as reliable as CD63 expression in the diagnosis of cat allergy. *J Immunol Methods* 2007;320:40–48
17. Hausmann OV, Gentinetta T, Fux M, Ducrest S, Pichler WJ, Dahinden CA. Robust expression of CCR3 as a single basophil selection marker in flow cytometry. *Allergy* 2011;66:85–91
18. Johansson SGO, Nopp A, van Hage M, Olofsson N, Lundahl J, Wehlin L et al. Passive IgE-sensitization by blood transfusion. *Allergy* 2005;60:1192–1199.
19. Schmid JM, Würtzen PA, Dahl R, Hoffmann HJ. Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy. *J Allergy Clin Immunol* 2014; 134: 741–744
20. Nopp A, Cardell LO, Johansson SGO, Oman H. CD-sens: a biological measure of immunological changes stimulated by ASIT. *Allergy* 2009;64:811–814
21. Patil SU, Shreffler WG. Immunology in the Clinic Review Series; focus on allergies: basophils as biomarkers for assessing immune modulation. *Clin Exp Immunol* 2012;167:59–66
22. Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. *Allergy* 2013;68:27–36
23. Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression--inhibitory effects of anti-inflammatory drugs. *J Allergy Clin Immunol* 2000;105:552–560
24. Yasnowsky KM, Dreskin SC, Efaw B, Schoen D, Vedanthan PK, Alam R et al. Chronic urticaria sera increase basophil CD203c expression. *J Allergy Clin Immunol* 2006;117:1430–1434
25. Mayorga C, Sanz ML, Gamboa PM, García BE, Caballero MT, García JM et al. In vitro

- 449 diagnosis of immediate allergic reactions to drugs: an update. *J Investig Allergol Clin Immunol*
 450 2010;20:103–109
 451
- 452 26. Hausmann OV, Gentinetta T, Bridts CH, Ebo DG. The basophil activation test in immediate-
 453 type drug allergy. *Immunol Allergy Clin North Am* 2009;29:555–566
 454
- 455 27. Ocmant A, Mulier S, Hanssens L, Goldman M, Casimir G, Mascart F et al. Basophil activation
 456 tests for the diagnosis of food allergy in children. *Clin Exp Allergy J Br Soc Allergy Clin*
 457 *Immunol* 2009;39:1234–1245
 458
- 459 28. Rubio A, Vivinus-Nébot M, Bourrier T, Saggio B, Albertini M, Bernard A. Benefit of the
 460 basophil activation test in deciding when to reintroduce cow's milk in allergic children.
 461 *Allergy* 2011;66:92–100
 462
- 463 29. Santos AF, Douiri A, Bécares N, Wu S-Y, Stephens A, Radulovic S et al. Basophil activation
 464 test discriminates between allergy and tolerance in peanut-sensitized children. *J Allergy Clin*
 465 *Immunol* 2015 Jan;135(1):179-86. doi: 10.1016/j.jaci.2014.09.001.
 466
- 467 30. Santos AF, Du Toit G, Douiri A, Radulovic S, Stephens A, Turcanu V et al. Distinct
 468 parameters of the basophil activation test reflect the severity and threshold of allergic
 469 reactions to peanut. *J Allergy Clin Immunol* 2015;135:179–186
 470
- 471 31. Gernez Y, Tirouvanziam R, Yu G, Ghosn EEB, Reshamwala N, Nguyen T et al. Basophil
 472 CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in
 473 subjects with nut allergy. *Int Arch Allergy Immunol* 2011;154:318–327
 474
- 475 32. Korošec P, Šilar M, Eržen R, Čelesnik N, Bajrović N, Zidarn M et al. Clinical routine utility of
 476 basophil activation testing for diagnosis of hymenoptera-allergic patients with emphasis on
 477 individuals with negative venom-specific IgE antibodies. *Int Arch Allergy Immunol*
 478 2013;161:363–368
 479
- 480 33. Sturm GJ, Jin C, Kranzelbinder B, Hemmer W, Sturm EM, Griesbacher A et al. Inconsistent
 481 results of diagnostic tools hamper the differentiation between bee and vespid venom allergy.
 482 *PloS One* 2011;6:e20842
 483
- 484 34. Eberlein B, Krischan L, Darsow U, Ollert M, Ring J. Double positivity to bee and wasp
 485 venom: Improved diagnostic procedure by recombinant allergen-based IgE testing and
 486 basophil activation test including data about cross-reactive carbohydrate determinants. *J*
 487 *Allergy Clin Immunol* 2012; 130: 155-161
 488
- 489 35. Eržen R, Košnik M, Silar M, Korošec P. Basophil response and the induction of a tolerance
 490 in venom immunotherapy: a long-term sting challenge study. *Allergy* 2012;67:822–830
 491
- 492 36. Kosnik M, Silar M, Bajrovic N, Music E, Korosec P. High sensitivity of basophils predicts
 493 side-effects in venom immunotherapy. *Allergy* 2005;60:1401–1406
 494
- 495 37. Gómez E, Campo P, Rondón C, Barrionuevo E, Blanca-López N, Torres MJ et al. Role of the

- 496 basophil activation test in the diagnosis of local allergic rhinitis. *J Allergy Clin Immunol*
497 2013;132:975–976.
498
- 499 38. Nopp A, Johansson SGO, Ankerst J, Bylin G, Cardell LO, Grönneberg R et al. Basophil
500 allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.
501 *Allergy* 2006;61:298–302
502
- 503 39. Dahlén B, Nopp A, Johansson SGO, Eduards M, Skedinger M, Adédoyin J. Basophil allergen
504 threshold sensitivity, CD-sens, is a measure of allergen sensitivity in asthma. *Clin Exp Allergy*
505 2011;41:1091–1097
506
- 507 40. Johansson SGO, Nopp A, Oman H, Ankerst J, Cardell LO, Grönneberg R et al. The size of the
508 disease relevant IgE antibody fraction in relation to ‘total-IgE’ predicts the efficacy of anti-IgE
509 (Xolair) treatment. *Allergy* 2009;64:1472–1477
510
511
512
513

514 **Figure 1: Assessing basophil response.**

515 The fraction of CD63⁺ basophils is plotted against log allergen concentration. Adapted from
516 (20) with permission from the authors.

517 A. **Basophil reactivity** is the dose (range) at which maximal response occurs. **Basophil**
518 **sensitivity** is the dose at which half of the maximal response occurs. *At high allergen
519 concentrations, basophil response may be suppressed.

520 B. A change in sensitivity toward higher allergen concentration is the most reproducible
521 basophil biomarker for reduced clinical sensitivity to allergen to date. Attempts to reduce the
522 number of BAT tests required to determine a significant change in basophil response have
523 focussed on identifying an allergen concentration at which a change in sensitivity can readily
524 be assessed (grey box).

525 C. Basophil response could also be assessed as area under the curve (AUC) with a log allergen
526 axis, or a similar composite measure reflecting both reactivity and sensitivity. Variation in
527 maximal basophil reactivity arises concurrently with, and may be inseparable from, a change
528 in sensitivity.

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544 **Conflict of interest**

545 AFS, BE, SUP, WGS, OVH obtained research funding, and BE and OVH received speaker honoraria from Bühlmann
546 Laboratories, Schoenenbuch, CH. BE received research funding from BD Biosciences, Erembodegem, Belgium. AN
547 received research funding from Novartis, Basel, CH. HJH, CM, MF, PR, DE, VS, MLS, TPP, PK, and EFK confirm
548 that there are no conflicts of interest.